^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CHO-H01

i
Other names: CHO-H01, CHO H01, glyco-engineered anti-CD20 antibody
Associations
Company:
Cho Pharma
Drug class:
CD20 inhibitor
Related drugs:
Associations
4ms
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1/2, N=37, Recruiting, Cho Pharma Inc. | N=11 --> 37 | Trial completion date: Feb 2024 --> Jun 2026 | Trial primary completion date: Nov 2023 --> Dec 2025
Enrollment change • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
lenalidomide • CHO-H01
over1year
New P1/2 trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CHO-H01